Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vanta BioscienceBOM:540729 -4.97%50 Net Debt Paydown Yield % is 217.39% as of Aug. 13, 2026. GuruFocus rates BOM:540729 with a GF Score™ of 50/100 and a GF Value™ of ₹11.81 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Vanta Bioscience ranks better than 98.47% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Vanta Bioscience's Net Debt Paydown Yield % was 217.39%.
Vanta Bioscience (BOM:540729) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Vanta Bioscience Net Debt Paydown Yield % Related Terms
Vanta Bioscience Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540729 vs TMO, DHR, IDXX: Net Debt Paydown Yield % Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience Net Debt Paydown Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 217.39% mean?
Vanta Bioscience (BOM:540729) has a Net Debt Paydown Yield % of 217.39% as of Aug. 13, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Vanta Bioscience and its competitors. According to the industry distribution chart, Vanta Bioscience ranks #3 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 1.5%.
Is Vanta Bioscience's Net Debt Paydown Yield % too high?
Vanta Bioscience's current Net Debt Paydown Yield % is 217.39%. Based on the distribution chart, Vanta Bioscience ranks #3 out of 196 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vanta Bioscience has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Net Debt Paydown Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #3 out of 196 companies for Net Debt Paydown Yield %. This places Vanta Bioscience in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Diagnostics & Research company?
A good Net Debt Paydown Yield % depends on the Medical Diagnostics & Research industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Vanta Bioscience and its competitors. Vanta Bioscience's current Net Debt Paydown Yield % is 217.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.81, compared to a current price of ₹20.67 — trading 75% above its estimated fair value. The current Net Debt Paydown Yield % is 217.39%. Vanta Bioscience's overall GF Score™ is 50/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Net Debt Paydown Yield % is 217.39% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹20.67 is trading 75% above its estimated GF Value™ of ₹11.81.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
Net Debt Paydown Yield %: 217.39%
GF Value™: ₹11.81 vs. price of ₹20.67 (75% above fair value)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
50GF Score
Get the complete analysis for BOM:540729
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
